KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Average (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Equity Average for 10 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 0.88% to $1.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 0.88% year-over-year, with the annual reading at $1.9 billion for FY2025, 1.02% up from the prior year.
  • Equity Average hit $1.9 billion in Q4 2025 for CRISPR Therapeutics AG, up from $1.8 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $2.6 billion in Q3 2021 to a low of $1.7 billion in Q1 2021.
  • Historically, Equity Average has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2024.
  • Biggest five-year swings in Equity Average: skyrocketed 145.4% in 2021 and later dropped 22.05% in 2022.
  • Year by year, Equity Average stood at $2.5 billion in 2021, then decreased by 22.05% to $1.9 billion in 2022, then dropped by 5.71% to $1.8 billion in 2023, then grew by 7.23% to $1.9 billion in 2024, then dropped by 0.88% to $1.9 billion in 2025.
  • Business Quant data shows Equity Average for CRSP at $1.9 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.8 billion in Q2 2025.